Target Audience
This activity has been designed to meet the educational needs of oncologists, surgeons and radiation therapists involved in the management of women with breast cancer.
Statement of Need/Program Overview
The options for systemic therapy of early breast cancer are rapidly evolving, creating an educational imperative regarding management strategies. This interactive symposium will utilize a case-based approach to highlight integration of emerging data on endocrine therapy and cytotoxic therapy into the treatment of women with primary breast cancer. Discussion will include how evaluation of a patients’ risk of relapse, results of clinical trials, risk/benefit ratios and patient preference each contribute to the selection of appropriate adjuvant therapy. Patterns of care data from community practice will also be discussed.
Educational Objectives
Upon completion of this activity, participants should be able to:
| • |
Counsel women with low-risk invasive disease about the absolute risks and benefits of adjuvant systemic therapy. |
| • |
Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits of adjuvant aromatase inhibitors and about switching or sequencing aromatase inhibitors after tamoxifen. |
| • |
Develop and explain a management strategy for treatment of premenopausal women with primary breast cancer in the adjuvant setting. |
| • |
Evaluate the emerging data on various adjuvant chemotherapy approaches, including dose-dense treatment and the use of taxanes, and explain the relevance to patients considering adjuvant chemotherapy regimens. |
| • |
Discuss the risks and benefits of endocrine intervention with women with DCIS and those at high risk of developing breast cancer. |
Faculty & Affiliations
Jay R Harris, MD
Professor and Chair
Department of Radiation Oncology
Dana Farber Cancer Institute
Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts
Philadelphia, Pennsylvania
Gabriel N Hortobagyi, MD
Professor of Medicine
Nellie B Connally Chair in Breast Cancer
Chairman, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas
Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Assistant Professor of Medicine
Department of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana
Monica Morrow, MD
Chairman, Department of Surgical Oncology
G Willing Pepper Chair in Cancer Research
Fox Chase Cancer Center
Philadelphia, Pennsylvania
CME Evaluation
An evaluation will be given to each participant at the conclusion of this activity.
Accreditation
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Educational Support
This event is supported by education grants from AstraZeneca Pharmaceuticals LP.
Disclosure Policy
As a provider accredited by the Accreditation Council for Continuing Medical Education it is the policy of Research To Practice to require the disclosure of any significant financial interests or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Faculty disclosures and disclosures of discussions unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.
Sponsorship Statement
Sponsored by Research To Practice.
|
